Kangenbei: Ginkgo biloba extract has been approved the EU CEP certificate

Wang Ruwei, executive vice president and director of Kangenbei [- 0.69% capital research report] (600572 SH), said at the investor exchange meeting that the company's Ginkgo biloba extract received the CEP certificate issued by the European Union in March this year After passing the on-site certification of cGMP, it can activate the EU sales of pharmaceutical raw materials Wang Ruwei said that the company's Ginkgo biloba extract is currently exported to the European Union as a chemical raw material and intermediate After cGMP certification, it can be exported and sold as a pharmaceutical raw material, which will be improved in the scope of use and product pricing On the other hand, obtaining cGMP also helps to enhance the brand effect of the company's ginkgo leaf industrial base Ginkgo biloba extract is another major source of revenue for Kangenbei in addition to drug sales Its subsidiary, Yunnan Xitao green Pharmaceutical Co., Ltd., has one of the largest extraction production bases in Yunnan Province, with an annual processing capacity of 6000 tons of Chinese herbal medicines and a production capacity of over 100 tons of Ginkgo biloba extract.